Venu Holding Corporation enters the post-earnings week with short sellers adding aggressively, the stock down nearly 7% over the past month, and a material lock-up expiry looming just three weeks out.
The short-interest build this week is the most striking feature of the tape. Short interest climbed 17% week-on-week to 4.5% of the free float — about 1.93 million shares — with the bulk of the increase arriving in a single overnight step between May 8 and May 11. That jump coincides almost exactly with the Q1 earnings release on May 15, which delivered a mixed picture: revenue of $3.9 million beat the $3.75 million estimate, but EPS came in at -$0.29 against an expected -$0.24. The net loss for Q1 narrowed year-on-year to $13.8 million from $18.1 million, so there is a improving trend in burn — but the headline miss gave shorts a fresh excuse to press. The ORTEX short score has moved from 42.2 to 46.8 across the week, a steady grind higher rather than a spike, suggesting the build is deliberate rather than reactive.
Borrow conditions tell a very different story from the positioning direction. Availability is extremely loose — 1,163% of short interest — meaning the lending pool dwarfs current demand by a wide margin. Cost to borrow has more than halved over the past month, dropping to 0.84% from above 2% in early April. That combination makes shorting the stock almost frictionless right now: unlimited supply, negligible rental cost. Options reinforce the call-heavy skew. The put/call ratio sits at just 0.097, fractionally below its 20-day average of 0.103, with a z-score of -0.85. Options buyers are not hedging — they are leaning bullish even as shorts accumulate.
The Street's formal coverage is thin and dated. One buy-rated analyst carries a $12.10 mean price target, but the most recent change on record is from September 2025, when Freedom Broker raised its target to $15.30. With the stock now at $3.74, those targets look significantly stale and should not be taken at face value. EPS momentum at the 90-day horizon ranks in the 99th percentile, which reflects the improving loss trajectory, but the 30-day EPS momentum sits at just the 38th percentile — the near-term beat rate is not particularly strong. The P/E multiple of 3.2x and EV/EBITDA of 5.4x are arithmetic artifacts of the loss-making structure rather than genuine valuation anchors at this stage.
The ownership picture has a near-term pressure point worth noting. A 90-day lock-up covering approximately 42.9 million shares — including common stock, warrants, Class B non-voting shares, and Series B preferred — expires on June 6, 2026. That is roughly three weeks away. Jay Roth, the founder and CEO, controls 34% of shares and has been buying: he purchased 62,500 shares at $4.00 in March and made smaller top-up purchases in February and January. Net insider buying over the past 90 days totalled around 76,700 shares at a cost of roughly $340,000. The buys are modest in absolute dollar terms but directionally consistent — the CEO has been adding at prices above where the stock trades today. Citadel Advisors also built a new 6.6% position (3.8 million shares) as of the March 10 13F, and Empery Asset Management initiated a fresh 1.7% stake in Q1. Both are meaningful additions for a name this small. The lock-up expiry, however, creates an overhang: with 42.9 million shares potentially freed on June 6 against a float already reflected in 4.5% short interest, the dynamic around that date is the clearest binary event on the calendar.
Among correlated peers, ARMK surged 17.7% on the week — a sharp divergence from VENU's 1.6% decline — while BALY dropped 9.3% and PENN slipped 3.2%. The peer moves are noisy, reflecting different underlying drivers, but VENU's relative underperformance against Aramark is notable given both sit in the broader venues-and-hospitality complex. The next pivotal marker for VENU is the June 6 lock-up expiry, where the intersection of insider-held supply, Citadel's new stake, and a shorts-building backdrop will make that week a critical read on where new equilibrium sits.
See the live data behind this article on ORTEX.
Open VENU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
